摘要
目的研究对新生儿重症吸入性肺炎采用沐舒坦联合地塞米松治疗的临床治疗效果。方法选取41例重症吸入性肺炎新生患儿作为此次观察组研究对象,并采用沐舒坦联合地塞米松进行治疗;另选取同期同症患儿41例作为对照组研究对象,仅采用地塞米松治疗。结果观察组患儿临床症状改善情况显著优于对照组,P<0.05;观察组治疗效果优于对照组,P<0.05。结论对于重症吸入性肺炎新生患儿采用沐舒坦联合地塞米松治疗能够有效改善患儿临床症状,治疗效果较好。
Objective To study the curative effect of Mucosolvan combined with Dexamethasone in newborns with severe aspiration pneumonitis. Methods41 newborns with severe aspiration pneumonitis were selected as observation group. The observation group adopted Mucosolvan combined with Dexamethasone; in addition, 41 newborns with the same symptoms were selected as control group; the control group adopted Dexamethasone.ResultsThe improvement of clinical symptom of observation group was significantly better than that of control group （P〈0.05）; the treatment effect of observation group was better than that of control group （P〈0.05）.Conclusion： For newborns with severe aspiration pneumonitis, Mucosolvan combined with Dexamethasone can efficiently improve the clinical symptoms and has a favorable treatment effect.
出处
《中国卫生标准管理》
2015年第26期87-89,共3页
China Health Standard Management
关键词
新生儿
重症吸入性肺炎
沐舒坦
地塞米松
疗效观察
Newborns
Severe Aspiration Pneumonitis
Mucosolvan
Dexamethasone
Curative Effect Observation
